Skip to main content
. 2022 Mar 27;14(4):720. doi: 10.3390/pharmaceutics14040720

Figure A2.

Figure A2

(a) Anterior and posterior whole-body planar gamma images of a patient with colorectal liver metastases 1 h after intravenous administration of 177Lu2O3-iPSMA nanoparticles (185 MBq), (b) Abdominal SPECT imaging of a patient with multiple colorectal liver metastases 1 h after intravenous administration of 177Lu2O3-iPSMA nanoparticles (185 MBq), (c) Abdominal SPECT/CT imaging of a patient with multiple colorectal liver metastases 1 h after intravenous administration of 177Lu2O3-iPSMA nanoparticles (185 MBq).